Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06697301 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
A Phase 2 study of Advanced Melanoma, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 740
- Enrollment target
- 20
- Study locations
NCT06697301 is a Phase 2 study of Advanced Melanoma that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 740 participants, above the 137-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (440% higher). The trial reports 20 study locations across 18 states.
The verdict
NCT06697301, a Phase 2 study of Advanced Melanoma, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 740 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Conditions Studied
Interventions
- DRUG EIK1001
- DRUG Pembrolizumab (KEYTRUDA® )
Study Locations (20)
California
- Helios Clinical Research - Los Angeles
- Providence Medical Foundation - Santa Rosa
Missouri
- MidAmerica Cancer Care - Kansas City
- Washington University School of Medicine in St. Louis - St Louis
Arizona
- Ironwood Cancer & Research Centers - Chandler
Arkansas
- Genesis Cancer and Blood Institute - Hot Springs
Colorado
- UCHealth Memorial Hospital Central - Colorado Springs
Florida
- Bioresearch Partner - Hialeah
Maryland
- The Center for Cancer and Blood Disorders - Bethesda
Ohio
- Gabrail Cancer Center Research LLC - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2040-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06697301
The ClinicalTrials.gov registry entry for NCT06697301 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 740 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 137-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (440% higher). The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which EIK1001 is the first listed.
NCT06697301 reports 20 study locations spanning 18 distinct geographic areas - top geographies include California, Missouri, Arizona.
Frequently Asked Questions
What is clinical trial NCT06697301 about?
NCT06697301 is a clinical study titled "Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.". The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
What is the current status of trial NCT06697301?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 740 participants. The study started on 2025-05-22. Estimated completion is 2040-12.
What conditions does trial NCT06697301 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT06697301?
The interventions under investigation include: EIK1001 (DRUG), Pembrolizumab (KEYTRUDA® ) (DRUG).
Who is sponsoring clinical trial NCT06697301?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06697301 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
RECRUITING · Phase 2
-
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.